Research Article

Antimalarial Activity of *Meriandra dianthera* Leaf Extracts in *Plasmodium berghei*-Infected Mice

Kalay Hagazy,¹ Gereziher G. Sibhat,² Aman Karim ,² Gebretsadkan H. Tekulu ,² Gomathi Periasamy,² and Mebrahtom G. Hiben ²

¹Department of Pharmacy, College of Health Sciences, P.O. Box 298, Aksum University, Axum, Ethiopia

²Department of Pharmacognosy, School of Pharmacy, College of Health Sciences, Mekelle University, P.O. Box 1871, Mekelle, Ethiopia

Correspondence should be addressed to Gebretsadkan H. Tekulu; gebretsadkan.hintsa@mu.edu.et

Received 3 October 2019; Revised 21 December 2019; Accepted 16 January 2020; Published 12 February 2020

Academic Editor: Ademar A. Da Silva Filho

Copyright © 2020 Kalay Hagazy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate the antimalarial effect of aqueous methanolic extract and solvent fractions of *Meriandra dianthera* leaves against *Plasmodium berghei* in mice model. **Method.** *M. dianthera* leaves were extracted with 80% methanol and dried. The dried crude extract was then defatted and further fractionated with chloroform, ethyl acetate, and butanol. Acute oral toxicity test was performed as per the Organization for Economic Cooperation and Development guideline 425. Peter's 4-day suppressive test was used to determine the *in vivo* antimalarial activity of the extract and fractions. **Result.** The crude leaf extract of *Meriandra dianthera* showed parasite inhibition of 42.28% and 45.52% at doses of 400 and 600 mg/kg, respectively, as compared to the negative control. Moreover, the mice which received chloroform and aqueous fractions at the dose of 400 mg/kg/day showed significant ($P < 0.001$) chemosuppression compared to the negative control. Both the extract and fractions were able to prevent *P. berghei* induced body weight loss and body temperature reduction and also increased the survival time of the mice as compared to the negative control. The aqueous methanolic leaf extract of *M. dianthera* showed no gross signs of toxicity or mortality in mice until a single oral dose of 2000 mg/kg. **Conclusion.** The extracts of *M. dianthera* leaves showed promising antimalarial activity, with no sign of toxicity and therefore may support its traditional use for the treatment of malaria.

1. Introduction

Malaria is a preventable and curable disease, yet it remains an overwhelming tropical disease, with high infection and mortality data [1]. It is caused by a protozoan parasite belonging to the genus *Plasmodium* [2]. More than one hundred different species of *Plasmodium* exist and produce malaria in many types of animals. Five of the *Plasmodium* species can cause malaria in humans (*Plasmodium falciparum*, *P. vivax*, *P. ovale*, *P. malariae*, and *P. knowlesi*) and two of these, *P. falciparum* and *P. vivax*, were reported as the greatest threat and most frequent human malaria causing species [3]. According to the World Health Organization (WHO) Malaria Report 2019, roughly 228 million cases and 405,000 deaths from malaria were estimated in the year 2018 worldwide. More than 90% of the cases and deaths were in

Africa and approximately 70% of the global deaths from malaria were in under-five children [4].

Despite using insecticide-treated bed nets, artemisinin-based combination treatments, and indoor residual spraying interventions, malaria accounts for 17% of outpatient visits, 15% of hospital admissions, and 29% of in-patient deaths in Ethiopia [5]. The Federal Ministry of Health (FMOH) of Ethiopia estimates that there are about 12 million suspected malaria cases annually. *P. falciparum* and *P. vivax* account roughly for 65% and 35% of malaria cases, respectively [6]. About 68% (57.3 million) of the country's population is at high risk of being infected with malaria.

Even though the WHO has planned to eradicate malaria, it continues to be the top leading health problems in Africa. This is attributed to the emergence and spread of drug-resistant parasites, insecticide-resistant *Anopheles*, absence

of a successful malaria vaccine, a geosociopolitic ruckus that increases travel [7], and rapidly raising distribution of counterfeit antimalarial drugs [8].

In malaria-endemic countries, natural and traditional medicines are commonly used to treat malaria. Over 160 families of plants with over 1200 species are recognized as traditional medicines used for malaria treatment. Of these, several medicinal plants have been scientifically confirmed by *in vitro* and/or *in vivo* tests for the claimed activity against malaria [9]. *Meriandra dianthera* (Roth.) (syn. *M. benghalensis*, Labiatae), locally known as “mesaguh” (Tigrigna) [10], is a branched aromatic shrub which grows up to 2 m in height. It is native to the high plateau of Ethiopia, Eritrea, Yemen, and Saudi Arabia. The leaf extract of *M. dianthera* is widely used as a folk medicine for the treatment of malaria, diabetes, diarrhea, ascariasis, and hypertension [10, 11]. The aqueous leaf extract of the plant in the form of juice is taken for five days to treat malaria in Seharti Samre, Ethiopia [11].

Limited scientific works exist that intend to verify the traditional claims of this plant. Four abietane diterpenoids isolated from *M. dianthera* root extract were reported to have a potent cytotoxic effect against different cancer cell lines as well as antibacterial activities [12]. Moreover, an essential oil extracted from *M. dianthera* aerial parts was reported to demonstrate promising anticancer effect against all cancer cell lines (IC₅₀ values ranged from 83.6 to 91.2 µg/mL) and considerable antibacterial, antifungal, and anti-oxidant properties [13]. Furthermore, methanolic leaves extract of *M. dianthera* showed significant *in vitro* α-amylase and α-glucosidase inhibitory activities as well as *in vivo* antidiabetic effect in alloxan-induced diabetic rats [14, 15]. As there is no scientific work that verifies the traditional antimalarial claim of *M. dianthera*, the present study was aimed to investigate the *in vivo* antimalarial activity of *M. dianthera* leaf extract using mice model.

2. Materials and Methods

2.1. Plant Material Collection. The leaves of *M. dianthera* were collected in November 2016 from Maynebri, which is located around Hiwane town in Tigray (this town has a latitude and longitude of 13°6'18"N and 39°29'48"E), Ethiopia. The plant was authenticated by Mr. Melaku Wondafrash and a voucher specimen (Collection No. KH001) was deposited in the National Herbarium, Addis Ababa University. The leaves were shade dried at room temperature and powdered with mortar and pestle.

2.2. Experimental Animals. Swiss albino female mice 8–12 weeks old were used to perform the acute oral toxicity test. Male Swiss albino mice (weighing 24–30 g and aged 6–8 weeks) were used in the antimalarial activity study. The mice were housed in a ventilated room, allowed to acclimatize for one week before the study and exposed to a 12 h light/dark cycle and had free access to standard pellets and water *ad libitum*. Chloroquine-sensitive *Plasmodium berghei* ANKA strain (provided by Ethiopian Public Health Institute) was

used for the experiment and maintained by subsequent passage of blood from infected donor mouse to the healthy mouse every 5 days.

2.3. Preparation and Fractionation of the Crude Extract. Powdered plant material (1.3 kg) was soaked in 6.5 L of 80% methanol (Carlo ERBA reagents SAS, France) and occasionally kept on an orbital shaker at 130 rpm for three days. After 72 h, the extract was filtered and the residue was macerated twice in a similar manner. The filtrates were combined, concentrated with a rotary evaporator (Stuart, SO1, UK), and dried in an oven (Genlab, England) at 40°C.

The crude extract was fractionated according to Kupchan's method by suspending 25 g of the crude extract in aqueous methanol (90%) and subsequently defatted with petroleum ether (Blulux Laboratories Ltd., India) and dried. Further, 22 g of dried defatted extract was suspended in distilled water (200 ml) and fractionated with chloroform (Carlo ERBA reagents SAS, France), ethyl acetate (Carlo ERBA reagents SAS, France), and *n*-butanol (Carlo ERBA reagents SAS, France) four times for each solvent (200 ml) [16, 17]. All four fractions were concentrated using a rotary evaporator, dried in an oven at 40°C, and stored in a refrigerator at −4°C in airtight containers.

2.4. Acute Oral Toxicity Test. Acute oral toxicity test for the crude extract was conducted on a group of five mice (nulliparous female Swiss albino) following the Organization for Economic Cooperation and Development (OECD) 425 guidelines to determine the safe dose for the antimalarial activity study [18]. The mice were deprived of food but not water for 3 h before oral administration of a single dose of the crude extract. Initially, one mouse was given the extract orally at a dose of 2000 mg/kg dissolved using 2% tween 80 in distilled water (v/v) by oral gavage and observed for 24 h. Later, the remaining four mice were given the same dose of the extract as the first mouse and were observed continuously for the first 30 min, intermittently for 4 h over a period of 24 h, and daily for 14 days. Mice were observed for change of general behavior and physiological signs of toxicity [18]. Oral acute toxicity study of the solvent fractions was conducted as per the method described for the crude extract.

2.5. Experimental Design. A total of 15 groups each containing six mice were used to evaluate antimalarial activity of the crude extract and solvent fractions. The first five groups served for crude extract and the remaining ten groups for the solvent fractions.

2.6. In Vivo Antimalarial Activity Test. To evaluate the *in vivo* antimalarial activity of the plant extracts, we adopted Peters' 4-day suppressive test using *P. berghei*-infected mice model [19]. Blood was obtained from the donor mice (that have 20–30% parasitaemia level) through jugular vein puncture and collected in Petri dish containing 0.5% trisodium citrate. The blood was then diluted with physiological saline (0.9%)

based on parasitaemia level of the donor mice to prepare a blood suspension in which there were approximately 5×10^7 infected erythrocytes per milliliter. Each mouse was injected intraperitoneally with 0.2 ml of blood suspension.

Three hours after the inoculation of the parasite, the mice in the three treatment groups orally received different doses of the crude extract (200, 400, and 600 mg/kg) for four consecutive days. The negative and positive control groups received vehicle (2% tween 80 in distilled water (v/v)) and 25 mg/kg chloroquine phosphate (EPHARM, Ethiopia), respectively. The fractions, chloroform, ethyl acetate, butanol, and aqueous, were also evaluated for their antimalarial activity by the same procedure at the dose of 200 mg/kg and 400 mg/kg.

$$\begin{aligned}\% \text{ parasitaemia} &= \frac{\text{number of parasitized RBC}}{\text{total number of RBC count}} \times 100, \\ \% \text{ suppression} &= \frac{\text{parasitaemia level of negative control} - \text{parasitaemia level of test group}}{\text{parasitaemia level of negative control}} \times 100.\end{aligned}\quad (1)$$

2.6.1. Determination of Body Weight and Temperature. The body weight of each mouse in all groups was recorded on day 0 and after infection on day 4. The rectal temperature of mice was measured with a digital thermometer to see the effect of the extract and fractions on the prevention of body temperature reduction due to malaria [22].

2.6.2. Determination of Mean Survival Time. The mice were monitored daily to see if there is any mortality and the number of days from the time of inoculation of the parasite up to death was recorded for each mouse in all groups throughout the follow-up period. The mean survival time (MST) for each group was calculated as follows [23]:

$$\text{MST} = \frac{\text{sum of the survival time of mice in a group (days)}}{\text{total number of mice in that group}}.\quad (2)$$

2.7. Phytochemical Screening. The crude plant extract was screened to identify various classes of chemical constituents following the methods described by Trease and Evans [24].

2.8. Statistical Analysis. The data were analyzed using SPSS version 21. The results are reported as mean $\pm$ SEM. One-way analysis of variance (ANOVA) followed by Tukey's HSD *post hoc* test was used to compare results among and within the groups. The results were considered significant when $P < 0.05$.

3. Results

3.1. Acute Oral Toxicity Test. The crude leaves extract of *M. dianthera* showed no signs of toxicity in mice during 14-day

Blood was collected from the tail of each mouse on day four, and thin blood smears were prepared on the frosted microscopic slides (Narang Medical Ltd., UK). The smears were fixed with methanol and stained with a 10% giemsa solution, wetted at the top with a drop of oil immersion, and examined under a compound microscope (Optica Microscopes, Italy) with an objective lens of 100x magnification power. The parasitaemia was determined by counting a minimum of four fields per slide with 200 RBC per field approximately [20]. Percent parasitaemia and percent parasitaemia suppression were calculated using the modified formula [21]:

observation period at a dose of 2000 mg/kg, signifying that the oral LD₅₀ of the extract is beyond 2000 mg/kg.

3.2. In vivo Antimalarial Activity of the Crude Extract. The hydromethanolic leaf extract of *M. dianthera* revealed dose-dependent suppressive activity but did not completely clear the parasite on day four (Table 1). Interestingly, analysis of parasitaemia level on day four revealed significant parasite suppression at the doses of 400 mg/kg ($P < 0.01$) and 600 mg/kg ($P < 0.001$) when compared to the negative control group. However, at the dose of 200 mg/kg, no significant chemosuppression was observed. The mice in the positive control group treated with chloroquine phosphate (CQ) at a dose of 25 mg/kg were free of any parasitaemia on day four.

For survival analysis, no mouse died in the positive control group up to 30th day after treatment, whereas all mice died in the negative control group on the 7th day after infection. The crude extract prolonged mean survival time of the study mice in a dose-dependent manner (Table 1), indicating that the extract might suppress *P. berghei* and hence diminished the overall pathologic effect of the parasite on the study mice. A significantly prolonged survival time compared to the negative control group was observed for groups that received 400 mg/kg/day ($P < 0.01$) and 600 mg/kg/day ($P < 0.001$) of the crude extract except the group treated with 200 mg/kg/day.

Compared to the negative control, the treatment groups received crude extract at all three dose levels which prevented rectal temperature reduction, although statistically not significant. The CQ treated group (25 mg/kg) showed significant ($P < 0.05$) increase in body temperature as compared to the negative control (Table 2).

The crude extract of *M. dianthera* also prevented weight loss in *P. berghei*-infected mice; though statistically not significant, each treatment group showed mean weight

TABLE 1: Effect of the hydromethanolic leaf extract of *M. dianthera* on mean parasitaemia level and mean survival time of *P. berghei*-infected mice.

Test sample	Dose (mg/kg)	% of parasitaemia	% of suppression	MST (days)
NC	10 ml/kg	44.10 ± 1.82	0.00	7.00 ± 00
Extract	200	38.43 ± 3.25 ^{c**}	14	7.83 ± 0.31
Extract	400	25.77 ± 2.41 ^{a*c**}	42.28	8.33 ± 0.33 ^{a*}
Extract	600	23.02 ± 1.88 ^{abc**}	45.52	8.67 ± 0.33 ^{a**}
CQ	25	00 ± 00 ^{a**}	100	ND

Results are presented as mean ± SEM; *n* = 6; ^awhen compared to negative control (NC); ^bwhen compared to 200 mg/kg of the extract; ^cwhen compared to CQ treated group; * *P* < 0.01; ** *P* < 0.001; CQ = chloroquine phosphate; ND = no death within the follow-up period; MST = mean survival time in days.

TABLE 2: Effect of the hydromethanolic leaf extract of *M. dianthera* on rectal temperature and body weight of *P. berghei*-infected mice.

Test sample	Dose (mg/kg)	Rectal temperature (°C)			Body wt. (g)		
		<i>D</i> ₀	<i>D</i> ₄	% of change	<i>D</i> ₀	<i>D</i> ₄	% of change
NC	10 ml/kg	36.0 ± 0.40	35.05 ± 0.08	-2.58 ± 1.00	29.15 ± 0.70	28.70 ± 0.82	-1.53 ± 0.71
Extract	200	35.90 ± 0.24	35.48 ± 0.26	-2.23 ± 1.09	29.97 ± 0.70	31.67 ± 0.65	1.95 ± 1.32
Extract	400	36.02 ± 0.29	35.78 ± 0.45	-0.64 ± 0.90	32.48 ± 0.80	33.38 ± 0.55	5.89 ± 1.66
Extract	600	36.40 ± 0.18	35.58 ± 0.25	-1.14 ± 0.83	29.54 ± 2.11	30.66 ± 2.06	4.02 ± 1.50
CQ	25	35.90 ± 0.24	36.28 ± 0.13	1.07 ± 0.49*	25.23 ± 0.56	25.54 ± 0.64	1.46 ± 2.82

Values are presented as Mean ± SEM, *n* = 6; CQ = chloroquine phosphate; NC = negative control; * *P* < 0.05 as compared to NC; *D*₄ = day 4; *D*₀ = day 0.

increase on the fifth day of infection when compared to the negative control and CQ treated groups (Table 2). But the increase in body weight is irregular that the highest weight gain was seen at the middle dose (400 mg/kg) followed by the high dose (600 mg/kg) and then the low dose (200 mg/kg). This could be due to the presence of appetite suppressant molecule(s) in the crude extract which could not have significant appetite suppressive effect at the lower dose but may suppress the appetite of the animals substantially while increasing the dose of the crude extract as the amount of the molecule(s) increases with dose.

3.3. *In vivo* Antimalarial Activity of the Solvent Fractions.

All the fractions reduced parasite load as compared to that of the negative control group as observed on day four after treatment. However, at the dose of 400 mg/kg of the chloroform fraction (CF) and aqueous fraction (AF), a statistically significant (*P* < 0.05) reduction in mean parasitaemia level was shown (Table 3). Even though insignificant (*P* > 0.05), an oral dose of the butanol (BF) and ethyl acetate fractions (EF) was also able to reduce the parasitaemia level. The standard drug chloroquine cleared parasitaemia to an undetectable level on the fifth day and the suppressive effect was statistically significant (*P* < 0.001) as compared to the negative control and all dose levels of the four fractions.

All dose levels of the *M. dianthera* solvent fractions moderately prolonged the mean survival time but chloroform fraction at a dose of 400 mg/kg was able to significantly (*P* < 0.01) improve mean survival time of the mice as compared to the negative control group. CF at a dose of 400 mg/kg significantly prolonged survival time (*P* < 0.05) of mice as compared to BF treated and negative control groups. Chloroquine treated mice survived all of the 30-day follow-up, and improvement in survival periods was statistically significant (*P* < 0.001) in relation to the control and all fractions treated groups (Table 3).

As shown in Table 4, a clear difference was observed among infected mice treated with different doses of the four fractions and negative control in preventing the rectal temperature reduction. Among the four fractions, only chloroform fraction (400 mg/kg) was able to show a statistically significant difference (*P* < 0.01) in preventing the decrease in rectal temperature caused by *P. berghei* infection in mice compared with the negative control. Contrary to this, among the four fractions, EF200 mg/kg showed enhanced rectal temperature reduction significantly (*P* < 0.001) when compared with the AF400 mg/kg and QC25 mg/kg. Despite the difference among groups, dose-dependent protection of rectal temperature reduction was seen in all fractions except in the butanol fraction treated mice.

Further, the analysis of percent change in body weight, between days 0 and 4, revealed significantly greater protection against parasite-induced bodyweight reduction when compared to the negative control (Table 4). All the fractions except that of chloroform showed significant body weight increment as compared with CQ (25 mg/kg) treated group.

3.4. Phytochemical Analysis. Preliminary phytochemical screening of the crude extract of *M. dianthera* revealed the presence of alkaloids, saponins, steroids, phenols, tannins, flavonoids, and terpenoids.

4. Discussion

In this study, we evaluated the *in vivo* antimalarial activity, safety profile, and chemical constituents of the crude leaf extract and solvent fractions to validate the traditional claim of *M. dianthera* for its use in the treatment of malaria.

In the *in vivo* antimalarial study, we found a dose-dependent chemosuppressive effect by crude leaf extract and solvent fractions of *M. dianthera* against *Plasmodium*

TABLE 3: Effect of solvent fractions of *M. dianthera* on mean parasitaemia level and mean survival time of *P. berghei*-infected mice.

Fraction/drug	Dose (mg/kg)	% of parasitaemia	% of suppression	MST (days)
NC	10 ml/kg	43.5 ± 1.52	0.00	7.33 ± 0.21
AF	200	36.27 ± 5.26	13.50	8 ± 0.45
	400	28.68 ± 3.00 ^{a*}	34.07	8.5 ± 0.5
BF	200	38.07 ± 1.92	13.30	8.17 ± 0.60
	400	31.90 ± 3.42	23.30	7.67 ± 0.21 ^{b*}
CF	200	31.6 ± 1.56	24.30	8.5 ± 0.56
	400	28.18 ± 3.78 ^{a*}	35.21	10 ± 0.77 ^{a*}
EF	200	38.67 ± 1.42	7.51	8.17 ± 0.40
	400	34.70 ± 5.07	17.1	8 ± 0.37
CQ	25	0.00 ^{a**}	100.00	ND

Values are expressed as Mean ± SEM; $n=6$; CQ=chloroquine phosphate; NC=negative control; AF=aqueous fraction; BF, butanol fraction; CF=chloroform fraction; EF=ethyl acetate fraction; * $P < 0.05$; ** $P < 0.001$; ^awhen compared to NC; ^bwhen compared to CF400 mg/kg; ND=no death within the follow-up period; MST=mean survival time in days.

TABLE 4: Effect of solvent fractions of *M. dianthera* on rectal temperature and body weight of *P. berghei*-infected mice.

Test sample	Dose (mg/kg)	Rectal temperature (°C)			Body wt. (g)		
		D_0	D_4	% of change	D_0	D_4	% of change
NC	10 ml/kg	36.35 ± 0.16	35.5 ± 0.32	-2.32 ± 1.17	25.48 ± 2.22	25.07 ± 2.07	-1.40 ± 1.40
AF	200	36.1 ± 0.36	35.53 ± 0.31	-1.67 ± 1.11 ^{b*}	24.3 ± 1.75	25.9 ± 2.03	6.38 ± 1.24 ^{d***}
	400	35.9 ± 0.23	36.33 ± 0.25	1.22 ± 0.80 ^{c***}	24.3 ± 1.75	25.9 ± 2.03	6.38 ± 1.24 ^{d***}
BF	200	36.8 ± 0.46	36.97 ± 0.29	0.47 ± 1.28 ^{c***}	24.23 ± 1.79	26.25 ± 0.81	8.5 ± 1.3 ^{c**d***}
	400	36.8 ± 0.41	36.17 ± 0.19	-1.79 ± 1.1 ^{b***}	24.02 ± 1.65	25.82 ± 0.94	8.5 ± 3.1 ^{c*d***}
CF	200	36 ± 0.25	36.1 ± 0.19	0.29 ± 0.69 ^{c***}	28.43 ± 0.84	29.38 ± 0.71	3.43 ± 0.84 ^{d*}
	400	35.17 ± 1.24	36.17 ± 1.04	2.98 ± 0.84 ^{d**}	26.83 ± 2.48	27.68 ± 0.11	3.87 ± 1.85 ^{d*}
EF	200	36.68 ± 0.17	34.13 ± 0.21	-6.9 ± 0.9 ^{a***c}	22.13 ± 0.80	23.65 ± 0.97	5.23 ± 2.19 ^{d**c}
	400	36.03 ± 0.11	35.52 ± 0.19	-0.43 ± 0.61 ^{bc*}	23.18 ± 1.13	25.37 ± 1.12	9.6 ± 1.8 ^{c*d***c}
CQ	25	36.87 ± 0.30	36.92 ± 0.29	0.15 ± 0.47 ^{c**}	30.67 ± 1.14	30.9 ± 0.73	1.04 ± 1.67

Values are presented as Mean ± SEM; $n=6$; CQ, chloroquine phosphate; NC, negative control; AF, aqueous fraction; BF, butanol fraction; CF, chloroform fraction; EF, ethyl acetate fraction; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; ^acompared to AF 400 mg/kg; ^bcompared to CF 400 mg/kg; ^ccompared to EF 200 mg/kg; ^dcompared to NC; ^ecompared to CQ treated group.

berghei compared to the negative control. More significant suppressive effects were noted at 400 mg/kg and 600 mg/kg dose level. The chemosuppression activity of the crude extract was in a dose-dependent manner which could be attributed to the concentration of schizonticidal compounds in the extract [1, 25]. This antimalarial activity observed in *M. dianthera* plant extract is in agreement with the other studies on different plant species of Lamiaceae family. The extract of *Solenostemon monostachyus* progressively reduced parasitaemia induced by chloroquine-sensitive *P. berghei* infection in prophylactic (28.48–71.72%), suppressive (12.52–72.47%), and curative (22.4–82.34%) models in mice [26]. The isolated compound from the ethanol extract of the dried root barks of *Ocimum sanctum* exhibited comparable activity to chloroquine and amodiaquine [27]. From the study of Kirmizibekmez et al., two flavonoid glycosides isolated as the major antimalarial constituents from *Phlomis brunneogaleata* showed activity with IC_{50} values of 5.4 and 12.7 μ M against the *Plasmodium falciparum* K1 clones [28].

The crude extract has the highest antimalarial activity from all test samples in this study with chemosuppression of 42.28% and 45% ($P < 0.001$) at doses of 400 mg/kg and 600 mg/kg, respectively, compared to the negative control. From the solvent fractions, the aqueous and chloroform fractions (400 mg/kg) exhibited the highest chemosuppression (34% and 35.4%) ($P < 0.05$). The ethyl acetate and

butanol fractions moderately inhibited the parasite growth but the suppression was not statistically significant compared to the negative control.

Furthermore, the mice treated with crude extract at middle and higher doses as well as CF at a dose of 400 mg/kg survived significantly ($P < 0.05$) as compared to the negative control. In addition, as weight loss and body temperature reduction are the general features of malaria-infected mice [29], the antimalarial active agents are expected to prevent body weight loss in *P. berghei*-infected mice. In this study, the crude leaf extract and solvent fractions of *M. dianthera* prevented weight loss in a dose-dependent manner. Interestingly, all the fractions at the highest dose significantly prevented weight loss which could be due to appetite enhancing and immunomodulatory components in the fractions [30].

Fever is one key manifestation of human malaria but in the case of *P. berghei*-infected mouse model, malaria is associated with a decrease in body temperature [31]. In this experiment, the crude extract and fractions were unable to significantly prevent rectal temperature reduction compared to negative control but the chloroform fraction at 400 mg/kg ($P < 0.01$) significantly prevented temperature reduction compared to crude extract and other fractions.

In vivo tests have advantages over *in vitro* tests as it takes into account the possible effects of the test samples as

a prodrug and their role in modifying the immune system for the suppression of infection in a living host [1, 32]. Multiple other *in vivo* studies on rodent malaria using diverse plant species from Ethiopia and researchers from other countries have reported antimalarial activity of medicinal plants including *Withania somnifera* [22], *Dodonaea angustifolia* [33], and *Osyris quadripartita* [34]. The scarcity of previous reports pertaining to the antimalarial activity of *M. dianthera* including the relative composition and predominance of its leaf chemicals could not permit a discussion from a comparative perspective. This is the first scientific report that shows the antimalarial activity of the genus *Meriandra*. From the Lamiaceae family, *in vitro* antiplasmodial activity of the seventeen solvent extracts and eleven essential oils of *Salvia* species displayed antiplasmodial activity [35], which is in agreement with this study. Similarly, solvent fractions of *Solenostemon monostachyus*, isolated compounds obtained from *Ocimum sanctum*, and *Phlomis brunneogaleata* have exerted good antiplasmodial activity which are consistent with the results of the current study [26–28]. In the acute toxicity study, after administration of crude leaf extract *M. dianthera*, all the mice were found physically active and no gross behavioral changes or other signs of toxicity were observed till the end of the follow-up period. This indicates that the test extract and solvent fractions may be safe up to a dose of 2000 mg/kg body weight [18].

The preliminary phytochemical tests of crude leaf extract of *M. dianthera* revealed the presence of alkaloids, saponins, terpenoids, tannins, flavonoids, and steroids which were also detected by Demoz and his team in an earlier study [36]. However, further work to isolate active constituents was not performed since the parasite suppression effect by the crude extract was more potent than the different fractions tested which may imply that considering additive and/or synergistic effect may be more important than considering individual components. Yet, previous studies reported essential oils and components therein including camphor, terpineol, pinocarveol, verbenol, caryophyllene oxide, ledol, isolongifolene, borneol, spathulenol, thymoquinone, β -eudesmol, and thymol [13] as well as bioactive fatty acid methyl esters including palmitic acid methyl ester, α -linolenic acid methyl ester, and other benzene derivatives in *M. dianthera* leaves [14]. These essential oils [37–39] and fatty acid esters were reported to demonstrate significant *in vitro* and *in vivo* antiplasmodial activities [40–42]. Besides the antiplasmodial effect, both the essential oils and fatty acid methyl esters were reported to exhibit *in vitro* α -glucosidase and α -amylase inhibitory effects [13, 15]. Also, the essential oils exerted anticancer, antimicrobial, and antioxidant property [13], and the fatty acids exhibited *in vivo* antidiabetic activity in rodent models [14].

Phytochemicals exert their antiplasmodial effect through different mechanisms. For example, alkaloids intercalate with the parasite DNA [43] and flavonoids and phenolics act by various mechanisms which include inhibiting the fatty acid biosynthesis (FAS II) of the parasite [34], elevating the red blood cell oxidation, inhibiting the parasite's protein

synthesis, and counteracting the oxidative stress induced by the malaria parasite [44]. The extract and fractions of *M. dianthera* may have exerted their action through the mechanisms mentioned above or by some other unknown mechanism. Hence, the extract and fractions which showed main antiplasmodial activity could be due to additive and/or synergistic action.

5. Conclusion

In this study, the crude extract and solvent fractions of *M. dianthera* leaves inhibited the growth of *P. berghei* in a dose-dependent manner. The chloroform and aqueous fractions showed the highest chemosuppressive effect among all the extracts. In terms of toxicity, the extracts can be considered safe until the dose of 2000 mg/kg. In addition, this study for the first time scientifically validates the traditional claim of the plant for its antimalarial property. Further phytochemical studies on the chloroform and aqueous fraction are recommended to identify the active constituents, which may contain potential candidates to be developed as an antimalarial drug.

Data Availability

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The study was approved by the Institutional Ethics Review Committee, Mekelle University (ERC no. 1025/2017).

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors' Contributions

All authors were involved in concept and design development, participating in experimentation, data collection and statistical analysis, manuscript preparation, manuscript edition, and manuscript revision. Particularly, KH designed and performed the experiments, analyzed the results, and was a major contributor in writing the manuscript. GGS and AK designed the study and criticized the methods employed. GHT, MGH, and GP assessed the experimentation and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors are grateful to Mr. Melaku Wondafrash, Department of Botany, Addis Ababa University, for authenticating the study plant and the Ethiopian Public Health Institute for providing *Plasmodium berghei* ANKA strain. This study was financially supported by Mekelle University.

References

- [1] L. Alli, A. Adesokan, and A. Salawu, "Antimalarial activity of fractions of aqueous extract of *Acacia nilotica* root," *Journal of Intercultural Ethnopharmacology*, vol. 5, no. 2, pp. 180–185, 2016.
- [2] A. Bosman, C. Delacollette, P. Olumese et al., *The Use of Antimalarial Drugs: Report of an Informal Consultation*, Vol. 8, Roll Back Malaria World Health Organization, Geneva, Switzerland, 2001.
- [3] T. F. de Koning-Ward, M. W. A. Dixon, L. Tilley, and P. R. Gilson, "Plasmodium species: master renovators of their host cells," *Nature Reviews Microbiology*, vol. 14, no. 8, pp. 494–507, 2016.
- [4] World Health Organization, *World Malaria Report 2019*, World Health Organization, Geneva, Switzerland, 2019.
- [5] Z. Petros, "The need of standardized herbal remedies as alternative sources of antimalarial products in Ethiopia: updated review," *Journal of Pharmacology Online*, vol. 3, pp. 1440–1447, 2011.
- [6] Y. Aschale, A. Mengist, A. Bitew, B. Kassie, and A. Talie, "Prevalence of malaria and associated risk factors among asymptomatic migrant laborers in West Armachiho District, Northwest Ethiopia," *Research and Reports in Tropical Medicine*, vol. 9, pp. 95–101, 2018.
- [7] N. Abdulrazak, U. Asiya, N. Usman, I. Unata, and A. Farida, "Antiplasmodial activity of ethanolic extract of root and stem bark of *Cassia sieberiana* DC on mice," *Journal of Intercultural Ethnopharmacology*, vol. 4, no. 2, pp. 96–101, 2015.
- [8] P. N. Newton, R. McGready, F. Fernandez et al., "Manslaughter by fake artesunate in Asia—will Africa be next?" *PLoS Medicine*, vol. 3, no. 6, Article ID e197, 2006.
- [9] B. Lawal, O. Shittu, A. Kabiru et al., "Potential antimalarials from African natural products: a review," *Journal of Intercultural Ethnopharmacology*, vol. 4, no. 4, pp. 318–343, 2015.
- [10] A. Teklay, B. Abera, and M. Giday, "An ethnobotanical study of medicinal plants used in Kilte Awulaelo District, Tigray region of Ethiopia," *Journal of Ethnobiology and Ethnomedicine*, vol. 9, no. 1, p. 65, 2013.
- [11] S. Araya, B. Abera, and M. Giday, "Study of plants traditionally used in public and animal health management in Seharti Samre District, Southern Tigray, Ethiopia," *Journal of Ethnobiology and Ethnomedicine*, vol. 11, no. 22, pp. 1–25, 2015.
- [12] R. A. Mothana, R. Gruenert, U. Lindequist, P. J. Bednarski, and R. Jansen, "Antimicrobial and cytotoxic abietane diterpenoids from the roots of *Meriandra benghalensis* (Roxb.) Benth," *Pharmazie*, vol. 64, no. 9, pp. 613–615, 2009.
- [13] R. A. Mothana, F. A. Nasr, J. M. Khaled et al., "Analysis of chemical composition and assessment of cytotoxic, antimicrobial, and antioxidant activities of the essential oil of *Meriandra dianthera* growing in Saudi Arabia," *Molecules*, vol. 24, no. 14, p. 2647, 2019.
- [14] S. D. Mussie, P. G. Kareru, J. M. Kericko, and G. N. Berhane, "Evaluation of the anti-diabetic potential of the methanol extracts of *Aloe camperi*, *Meriandra dianthera* and a polyherb," *Journal of Diabetes Mellitus*, vol. 5, no. 4, pp. 267–276, 2015.
- [15] M. Sium, P. Kareru, B. Kiage-Mokua, K. Sood, J. Langley, and J. Herniman, "In vitro anti-diabetic activities and phytochemical analysis of bioactive fractions present in *Meriandra dianthera*, *Aloe camperi* and a Polyherb," *American Journal of Plant Sciences*, vol. 8, no. 3, pp. 533–548, 2017.
- [16] S. M. Kupchan, R. W. Britton, M. F. Ziegler, and C. W. Sigel, "Bruceantin, a new potent antileukemic simaroubolide from *Brucea antidysenterica*," *The Journal of Organic Chemistry*, vol. 38, no. 1, pp. 178–179, 1973.
- [17] H. Otsuka, "Purification by solvent extraction using partition coefficient," in *Methods in Biotechnology Natural Products Isolation*, D. Sarker, Z. Latif, and A. Gray, Eds., Human Press, Totowa, NJ, USA, 2nd edition, 2006.
- [18] Organization for Economic Co-operation and Development (OECD), *Guideline for Testing Chemicals 425, Acute Oral Toxicity: Up-and-Down Procedure*, Organization for Economic Co-operation and Development (OECD), Washington, DC, USA, 2008.
- [19] W. Peters, B. L. Robinson, G. Tovey, J. C. Rossier, and C. W. Jefford, "The chemotherapy of rodent malaria. L. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. part 3: observations on 'Fenozan-50F', a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane," *Annals of Tropical Medicine & Parasitology*, vol. 87, no. 2, pp. 111–123, 1993.
- [20] B. Kalra, S. Chawla, P. Gupta, and N. Valecha, "Screening of antimalarial drugs: an overview," *Indian Journal of Pharmacology*, vol. 38, no. 1, pp. 5–12, 2006.
- [21] D. A. Fidock, P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka, "Antimalarial drug discovery: efficacy models for compound screening," *Nature Reviews Drug Discovery*, vol. 3, no. 6, pp. 509–520, 2004.
- [22] D. Dikasso, E. Mekonnen, A. Debelli et al., "Antimalarial activity of *Withania somnifera* L. dunal extracts in mice," *Ethiopian Medical Journal*, vol. 44, no. 3, pp. 279–285, 2006.
- [23] T. O. Elufioye and J. M. Agbedahunsi, "Antimalarial activity of *Tithonia diversifolia* (Asteraceae) and *Crossopteryx febrifuga* (Rubiaceae) on mice in vivo," *Journal of Ethnopharmacology*, vol. 93, no. 2-3, pp. 167–171, 2004.
- [24] G. Trease and W. Evans, *Pharmacognosy*, Bailliere Tindall, London, UK, 15th edition, 1989.
- [25] A. Tsado, L. Bashir, S. Mohammed et al., "Phytochemical composition and antimalarial activity of methanol leaf extract of *Crateva adansonii* in *Plasmodium berghei* infected mice," *British Biotechnology Journal*, vol. 6, no. 4, pp. 165–173, 2015.
- [26] O. Jude, A. D. Koofreh, and A. A. Bala, "Antipyretic and antimalarial activities of *Solenostemon monostachyus*," *Pharmaceutical Biology*, vol. 54, no. 4, pp. 648–653, 2016.
- [27] S. Zhu, "Small molecules with antimalarial activity," U.S. Patent 2013/0023552 A1, 2013.
- [28] H. Kirmizibekmez, I. Calis, R. Perozzo et al., "Inhibiting activities of the secondary metabolites of *phlomis brunneogaleata* against parasitic protozoa and plasmodial enoyl-ACP reductase, a crucial enzyme in fatty acid biosynthesis," *Planta Medica*, vol. 70, no. 8, pp. 711–717, 2004.
- [29] J. Langhorne, S. J. Quin, and L. A. Sanni, "Mouse models of blood-stage malaria infections: immune responses and cytokines involved in protection and pathology," *Chemical Immunology and Allergy*, vol. 80, pp. 204–228, 2002.
- [30] S. Fentahun, E. Makonnen, T. Awas, and M. Giday, "In vivo antimalarial activity of crude extracts and solvent fractions of leaves of *Strychnosmitis* in *Plasmodium berghei* infected mice," *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 13, 2017.
- [31] B. Mengiste, E. Makonnen, and K. Urga, "In vivo antimalarial activity of *Dodonaea angustifolia* seed extracts against *P. berghei* in mice model," *Momona Ethiopian Journal of Science*, vol. 4, no. 1, pp. 47–63, 2012.
- [32] L. Bantie, S. Assefa, T. Teklehaimanot, and E. Engidawork, "In vivo antimalarial activity of the crude leaf extract and solvent fractions of *Croton macrostachyus* Hocsht. (*Euphorbiaceae*)

- against *Plasmodium berghei* in mice,” *BMC Complementary and Alternative Medicine*, vol. 14, no. 1, 2014.
- [33] T. Deressa, Y. Mekonnen, and A. Animut, “*In vivo* antimalarial activities of *Clerodendrum myricoides*, *Dodonea angustifolia* and *Aloe debrana* against *Plasmodium berghei*,” *Ethiopian Journal of Health Development*, vol. 24, no. 1, pp. 25–29, 2010.
 - [34] S. Girma, M. Giday, B. Erko, and H. Mamo, “Effect of crude leaf extract of *Osyris quadripartita* on *P. berghei* in Swiss albino mice,” *BMC Complementary and Alternative Medicine*, vol. 15, no. 1, 2015.
 - [35] K. GPP, R. L. Van Zyl, H. Davids, F. R. van Heerden, A. C. U. Louren, and A. M. Viljoen, “Antimalarial and anticancer activities of selected South African *Salvia* species and isolated compounds from *S. radula*,” *South African Journal of Botany*, vol. 74, no. 2, pp. 238–243, 2008.
 - [36] M. S. Demoz, K. P. Gachoki, K. J. Mungai, and B. G. Negusse, “Ethnobotanical survey and preliminary phytochemical studies of plants traditionally used for diabetes in Eritrea,” *European Journal of Medicinal Plants*, vol. 9, no. 2, pp. 1–11, 2015.
 - [37] F. Tchoumboungang, P. H. Zollo, E. Dagne, and Y. Mekonnen, “*In vivo* antimalarial activity of essential oils from *Cymbopogon citratus* and *Ocimum gratissimum* on mice infected with *Plasmodium berghei*,” *Planta Medica*, vol. 71, no. 1, pp. 20–23, 2005.
 - [38] M. Dell’Agli, C. Sanna, P. Patrizia Rubiolo et al., “Antiplasmodial and insecticidal activities of the essential oils of aromatic plants growing in the Mediterranean area,” *Malar Journal*, vol. 11, no. 1, p. 219, 2012.
 - [39] O. E. Ogunjinmi, N. O. Olawore, and A. A. Aliyu, “Comparative studies of chemical constituents and antimalarial activity of essential oils extracted from the stem, root and fruit peel of *Citrus paradisi* grown in Nigeria,” *Journal of Applied Chemistry*, vol. 10, no. 12, pp. 1–11, 2017.
 - [40] N. M. Carballeira, “New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents,” *Progress in Lipid Research*, vol. 47, no. 1, pp. 50–61, 2008.
 - [41] P. Melariri, W. Campbell, P. Etusim, and P. Smith, “*In vitro* and *in vivo* antimalarial activity of linolenic and linoleic acids and their methyl esters,” *Advanced Studies in Biology*, vol. 4, pp. 333–349, 2012.
 - [42] J. E. Okokon, B. S. Antia, D. Mohanakrishnan, and D. Sahal, “Antimalarial and antiplasmodial activity of husk extract and fractions of *Zea mays*,” *Pharm Biol*, vol. 55, no. 1, pp. 1394–1400, 2017.
 - [43] S. Saxena, N. Pant, D. C. Jain, and R. S. Bhakuni, “Antimalarial agents from plant sources,” *Current Science*, vol. 85, no. 9, pp. 1314–1329, 2003.
 - [44] M. Builders, N. Wannang, and J. Aguiyi, “Antiplasmodial activities of *Parkiabiglobosa* leaves: *in vivo* and *in vitro* studies,” *Annals Biological Research*, vol. 2, no. 4, pp. 8–20, 2011.